SLS rallies as retail bets on trial wins and takeover buzz

SELLAS Life Sciences Group shares are up over 78% in a month as retail investors focus on positive Phase 2 leukemia trial results and takeover speculation. Traders are also watching for final event-driven data on the company Galinpepimut-S drug due by year-end, fueling hopes of a partnership or acquisition.